Sipavibart for preventing COVID-19 [ID6282]

  • In development
  • GID-TA11352
  • Expected publication date: TBC
Further to our last update on this topic, AstraZeneca has confirmed that it has withdrawn its application to the MHRA for a marketing authorisation for sipavibart.